tradingkey.logo

Tonix Pharmaceuticals And Makana Therapeutics Announce Collaboration Combining Tonix’S Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana’S Genetically Engineered Organs In Preclinical And Clinical Xenotransplantation Studies

ReutersApr 9, 2025 11:02 AM

- Tonix Pharmaceuticals Holding Corp TNXP.O:

  • TONIX PHARMACEUTICALS AND MAKANA THERAPEUTICS ANNOUNCE COLLABORATION COMBINING TONIX’S ANTI-CD40L MONOCLONAL ANTIBODY (TNX-1500) WITH MAKANA’S GENETICALLY ENGINEERED ORGANS IN PRECLINICAL AND CLINICAL XENOTRANSPLANTATION STUDIES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI